Vitality Watch

Dossier pubmed preclinical 23-sep-2026
Animal model, organoid, or cell-culture result — not yet human

Targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence.

Key claim: Targeted BIRC6 inhibition with antibody-conjugated LNP-ASOs reverses hematopoietic stem cell aging and immunosenescence by disrupting a bone-marrow Treg–cAMP–PKA–CREB–BIRC6 pathway that protects aged HSCs from apoptosis.

Abstract

Immunosenescence represents a central hallmark of organismal aging, characterized by a progressive decline in immune function, which compromises host defense and accelerates systemic aging. Hematopoietic stem cell (HSC) aging is a key contributor to this process, characterized by aberrant expansion, myeloid-biased differentiation, and impaired self-renewal, culminating in hematopoietic-immune imbalance. Although the expansion and survival advantages of aged HSCs have been well-demonstrated, the underlying mechanisms remain elusive. Here, we reveal that regulatory T cells (Tregs) within the bone marrow (BM) microenvironment actively safeguard the survival of aged HSCs via a previously uncharacterized signaling pathway. We identify a novel aged HSC subpopulation characterized by high expression of Baculoviral IAP Repeat Containing 6 (BIRC6), an apoptosis inhibitor. This BIRC6-high subpopulation is markedly expanded in aged mice and recapitulates the hallmarks of HSC aging. Mechanistically, cAMP derived from BM Tregs activates the PKA-CREB pathway in HSCs, activating Birc6 transcription, which reduces apoptotic priming in aged HSCs, thereby promoting hematopoietic-immune imbalance. Strikingly, targeted BIRC6 inhibition in HSCs using antibody-conjugated lipid nanoparticle-encapsulated antisense oligonucleotides (LNP-ASOs) significantly reverses hematopoietic-immune aging phenotypes and ameliorates age-associated immune dysfunction in middle-aged mice. LNP-ASO treatment dramatically rebalances immune cell production, reduces immunosenescence markers, and enhances vaccine responses in middle-aged mice. More importantly, this strategy was also effective in HSCs from middle-aged human donors, highlighting its potential for clinical translation. These findings elucidate a key microenvironmental pathway (Treg-cAMP-PKA-CREB-BIRC6) driving HSC aging and offer a novel strategy to ameliorate the aged hematopoietic system and combat age-related immune decline.

Why this matters

Most hematopoietic-aging mechanisms in the vault describe damage or drift without a druggable node; this finding names one (BIRC6) and pairs it with a delivery vehicle (antibody-conjugated LNP-ASO) already in the therapeutic toolkit. It also connects a bone-marrow niche immune cell (Treg) to a stem-cell-intrinsic apoptosis-resistance program, which is a structurally new causal chain for the immunosenescence roster. Effects remain in middle-aged mice plus ex vivo human HSCs — no lifespan, no in vivo human data.

Source

Link

Briefing card

Targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence.
Stage: preclinical · pubmed · 23-sep-2026

If you are tracking preclinical routes to rejuvenate the aging immune system, BIRC6 LNP-ASOs are a new HSC-targeted candidate with mouse data and ex vivo human-cell activity but no human trials.

Targeted BIRC6 inhibition with antibody-conjugated LNP-ASOs reverses hematopoietic stem cell aging and immunosenescence by disrupting a bone-marrow Treg–cAMP–PKA–CREB–BIRC6 pathway that protects aged HSCs from apoptosis.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1038/s41392-026-02787-1

build build 880 · 2bcef25 · 2026-11-18